RWE’s new dataset: Social media
Pharma is waking up to the potential of social media to enhance existing RWD sources and to offer altogether new insights in rare disease and beyond
Close log in window
Post pandemic, pharma and regulators are both working to accelerate the transformative power of electronic filing
The FDA is developing guidelines that will help pharma accelerate its adoption of RWE, this is what the industry should know
The FDA and other regulatory bodies are increasingly willing to accept real-world evidence as part of approvals. Pharma is up to the task
Convincing payers of the value of digital add-ons and of drug/device combinations requires pharma to demonstrate that patients and other sta...
